Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors.

Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors. - alpha-GI0,1,2,3+alogliptin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004259

Enrollment

120

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Taking alogliptin only Taking alpha-GI once a day in addition to alogliptin Taking alpha-GI twice a day in addition to alogliptin Taking alpha-GI thrice a day in addition to alogliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Type 2 Diabetic patients 2.Patients who are taking alpha-GI thrice a day. 3.HbA1c <JDS> level at baseline 6.5-9.0% 4.Subjects who provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are receiving insulin therapy. 2. Patients who are taking anti-diabetic medicines other than alpha-GI 3. Patients who have a severe hepatic dysfunction. 4. Patients who have a severe renal dysfunction 5. Patients whose doctor in charge judges as inappropriate for the inclusion

Design outcomes

Primary

Measure	Time frame
HbA1c, glycoalbumin	—

Secondary

Measure	Time frame
Body weight, adherence	—

Countries

Japan

Contacts

Public ContactKiyomi Masuda

Graduate School of Medicine, Yokohama City University Department of Endocrinology and Metabolism

t086051a@yokohama-cu.ac.jp045-787-2639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026